BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III;
BridgeBio: Next Chapter Begins After Attruby Approval
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, Europe, and Japan, the company expects to report results from registrational trials of infigratinib, encaleret, and BBP-418, and it could have as many as four products on the market by the end of 2026.
Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...
Attruby will be available at a recommended dose of 712 mg, taken twice daily, at a list price of $18,759.12 for a 28-day ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Investor's Business Daily on MSN1d
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart DrugBridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback